Wang Shengcai, Li Yanzhen, Zhang Jie, Ni Xin
Department of Otolaryngology Head and Neck Surgery,Beijing Children's Hospital,Capital Medical University,National Center for Children's Health,Beijing Key Laboratory for Pediatric Disease of Otolaryngology Head and Neck Surgery,Beijing,100045,China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Jun;36(6):477-482. doi: 10.13201/j.issn.2096-7993.2022.06.015.
Neurofibromatosis type 1(NF1) is an autosomal dominant genetic disease in which a mutation in the NF1 gene on chromosome 17q11.2 results in inactivation or down-regulation of neurofibromin. This results in a series of neurocutaneous lesions characterized by neurofibromatosis. Patients with plexiform neurofibromas(PN), as one of the main manifestations of NF1, often experience pain, dysfunction, skeletal deformities, changes in appearance and other symptoms. In severe cases, compression of the airways and vital organs occurs, and the PN is at risk of malignancy progression. At present, its treatment is still challenging. Surgery is the primary treatment for PN, but complete resection is often difficult. In recent years, chemotherapy for PN has become a hot topic. This article reviews the research progress in the pathogenesis, diagnosis and treatment of PN in recent years.
1型神经纤维瘤病(NF1)是一种常染色体显性遗传病,其中17q11.2染色体上的NF1基因发生突变,导致神经纤维瘤蛋白失活或下调。这会导致一系列以神经纤维瘤病为特征的神经皮肤病变。患有丛状神经纤维瘤(PN)的患者,作为NF1的主要表现之一,常经历疼痛、功能障碍、骨骼畸形、外观改变等症状。在严重情况下,会发生气道和重要器官受压,并且PN有恶性进展的风险。目前,其治疗仍然具有挑战性。手术是PN的主要治疗方法,但往往难以完全切除。近年来,PN的化疗已成为一个热门话题。本文综述了近年来PN在发病机制、诊断和治疗方面的研究进展。